Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 28.14 USD -0.65%
Market Cap: 1.4B USD
Have any thoughts about
Immunocore Holdings PLC?
Write Note

Immunocore Holdings PLC
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Immunocore Holdings PLC
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Immunocore Holdings PLC
NASDAQ:IMCR
Interest Income Expense
-ÂŁ344k
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Interest Income Expense
$570k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Interest Income Expense
ÂŁ12.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Interest Income Expense
-$29m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Interest Income Expense
$27.8m
CAGR 3-Years
N/A
CAGR 5-Years
110%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Interest Income Expense
-ÂŁ200k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
24%
No Stocks Found

Immunocore Holdings PLC
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

Immunocore Holdings PLC stands as a pioneering force in the field of immunotherapy, leveraging its proprietary T-cell receptor (TCR) technology to transform the treatment landscape for various severe diseases. Rooted in cutting-edge science, the British biotech firm develops novel therapeutic agents targeting cancer, infectious diseases, and autoimmune conditions. Its leading platform technology, known as ImmTACs (Immune Mobilizing Monoclonal TCRs Against Cancer), ingeniously redirects T-cells—an integral component of the immune system—to recognize and obliterate cancerous cells in a highly targeted manner. By focusing on ultra-specific peptide-major histocompatibility complex (pMHC) targets, Immunocore meticulously designs its therapies to minimize off-target effects and maximize efficacy in tackling conditions that have eluded traditional treatment methods. Financially, Immunocore operates through a strategic blend of commercial and collaborative partnerships, alongside its independent pipeline advancements. It generates revenue by licensing its innovative technology to larger pharmaceutical entities that seek to add cutting-edge biologics to their portfolios. Additionally, milestone and royalty payments from collaborative research initiatives contribute significantly to its financial foundation. These partnerships not only bolster Immunocore's revenue streams but also accelerate its research and development efforts, enabling a faster path to market for its groundbreaking treatments. As a result, the company stands at the confluence of science and commerce, channeling its unique TCR technology to make meaningful strides in medical innovation and patient care.

IMCR Intrinsic Value
113.04 USD
Undervaluation 75%
Intrinsic Value
Price

See Also

What is Immunocore Holdings PLC's Interest Income Expense?
Interest Income Expense
-344k GBP

Based on the financial report for Dec 31, 2023, Immunocore Holdings PLC's Interest Income Expense amounts to -344k GBP.

What is Immunocore Holdings PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
21%

The average annual Interest Income Expense growth rates for Immunocore Holdings PLC have been 21% over the past three years .

Back to Top